Geron Corporation to Present RYTELO Study Data at EHA 2026 Congress

Geron Corporation announced that the first real-world evidence study of RYTELO in patients with lower-risk myelodysplastic syndromes will be presented at the European Hematology Association 2026 Congress. The retrospective and prospective investigator-sponsored study, conducted at the Moffitt Cancer Center, reported safety and clinical efficacy of imetelstat in advanced, heavily transfusion dependent patients with LR-MDS, including patients with extensive prior therapies and after luspatercept failure. Data from the retrospective portion of the study will be presented at the EHA 2026 Congress. The data, from the retrospective portion of the investigator-sponsored study, evaluated imetelstat in 40 patients with lower-risk MDS treated at the Moffitt Cancer Center in a real-world setting following U.S. Food and Drug Administration approval. Patients included in the analysis had advanced, heavily transfusion-dependent disease and extensive prior treatment exposure, including prior luspatercept, erythropoiesis-stimulating agents, hypomethylating agents and lenalidomide. With 14-month follow-up, the analysis reported a red blood cell transfusion independence rate of 37.5% lasting at least eight weeks with several responses ongoing at the time of analysis and identified potential predictors of response. The safety profile observed in the study was generally consistent with the known safety profile of imetelstat. Cytopenias were reported as the most common Grade 3/4 adverse event. Exploratory analyses also suggested a trend toward improved responses when imetelstat was used within the first three lines of therapy. Geron will also have additional presentations at the EHA 2026 Congress and the American Society of Clinical Oncology 2026 Annual Meeting, including abstracts related to its ongoing myelofibrosis clinical programs. This includes an updated overall survival analysis in patients with myelofibrosis treated with imetelstat in the Phase 2 IMbark trial compared with real-world data.